Correction: Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference

[1]  P. Palma,et al.  Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010 , 2010, Journal of Translational Medicine.

[2]  P. Palma,et al.  Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference , 2010, Journal of Translational Medicine.

[3]  E. Bunnik,et al.  Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. , 2010, The Journal of infectious diseases.

[4]  Donata Medaglini,et al.  Intranasal immunization with vaccine vector Streptococcus gordonii elicits primed CD4+ and CD8+ T cells in the genital and intestinal tracts. , 2010, Vaccine.

[5]  Jerome H. Kim,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[6]  G. Vanham,et al.  Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies , 2009, Retrovirology.

[7]  A. Harandi,et al.  Local cytokine and inflammatory responses to candidate vaginal adjuvants in mice. , 2009, Vaccine.

[8]  L. Lopalco,et al.  P04-18. Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group , 2009, Retrovirology.

[9]  G. Scarlatti,et al.  P04-20. Humoral immune response in acute HIV-1 infection , 2009, Retrovirology.

[10]  H. Schuitemaker,et al.  P04-49 LB. Adaptation of HIV-1 envelope glycoprotein to humoral immunity at a population level , 2009, Retrovirology.

[11]  Sylvia Janetzki,et al.  "MIATA"-minimal information about T cell assays. , 2009, Immunity.

[12]  K. S. Kim,et al.  Susceptibility to Simian Immunodeficiency Virus Ex Vivo Predicts Outcome of a Prime-Boost Vaccine After SIVmac239 Challenge , 2009, Journal of acquired immune deficiency syndromes.

[13]  S. Klaschik,et al.  Therapeutic Applications and Mechanisms Underlying the Activity of Immunosuppressive Oligonucleotides , 2009, Annals of the New York Academy of Sciences.

[14]  W. Paxton,et al.  Mucin 6 in seminal plasma binds DC-SIGN and potently blocks dendritic cell mediated transfer of HIV-1 to CD4(+) T-lymphocytes. , 2009, Virology.

[15]  Bernard Verrier,et al.  Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic PLA nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccination. , 2009, Vaccine.

[16]  P. Leone,et al.  Development and use of SIV-based Integrase defective lentiviral vector for immunization. , 2009, Vaccine.

[17]  K. Überla,et al.  Retrovirology BioMed Central , 2008 .

[18]  A. Harandi,et al.  The Mucosal Adjuvant Effect of α-Galactosylceramide for Induction of Protective Immunity to Sexually Transmitted Viral Infection1 , 2009, The Journal of Immunology.

[19]  C. Herrera,et al.  Reverse Transcriptase Inhibitors as Potential Colorectal Microbicides , 2009, Antimicrobial Agents and Chemotherapy.

[20]  Q. Sattentau,et al.  International Network for Comparison of HIV Neutralization Assays: The NeutNet Report , 2009, PloS one.

[21]  W. Savino,et al.  Growth Hormone Modulates Migration of Developing T Cells , 2009, Annals of the New York Academy of Sciences.

[22]  P. Lindner,et al.  Urea-Mediated Cross-Presentation of Soluble Epstein-Barr Virus BZLF1 Protein , 2008, PLoS pathogens.

[23]  F. Buonaguro,et al.  Th2 Polarization in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus (HIV)-Infected Subjects, as Activated by HIV Virus-Like Particles , 2008, Journal of Virology.

[24]  R. Weiss,et al.  Llama Antibody Fragments with Cross-Subtype Human Immunodeficiency Virus Type 1 (HIV-1)-Neutralizing Properties and High Affinity for HIV-1 gp120 , 2008, Journal of Virology.

[25]  J. Heeney,et al.  Prevention of SIV Rectal Transmission and Priming of T Cell Responses in Macaques after Local Pre-exposure Application of Tenofovir Gel , 2008, PLoS medicine.

[26]  G. Luzi,et al.  Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  A. Das,et al.  Optimization of the doxycycline-dependent simian immunodeficiency virus through in vitro evolution , 2008, Retrovirology.

[28]  F. Miedema,et al.  Growth hormone resurrects adult human thymus during HIV-1 infection. , 2008, The Journal of clinical investigation.

[29]  F. Buonaguro,et al.  DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. , 2007, Vaccine.

[30]  M. Smyth,et al.  Calreticulin exposure increases cancer immunogenicity , 2007, Nature Biotechnology.

[31]  V. KewalRamani,et al.  Dendritic-cell interactions with HIV: infection and viral dissemination , 2006, Nature Reviews Immunology.

[32]  M. Wainberg,et al.  Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies? , 2006, Antiviral research.

[33]  S. Shalet,et al.  Pathophysiology of radiation-induced growth hormone deficiency: efficacy and safety of GH replacement. , 2006, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[34]  S. Zolla-Pazner,et al.  Nonneutralizing Antibodies Are Able To Inhibit Human Immunodeficiency Virus Type 1 Replication in Macrophages and Immature Dendritic Cells , 2006, Journal of Virology.

[35]  R. Eisenberg,et al.  Mucosal Administration of CpG Oligodeoxynucleotide Elicits Strong CC and CXC Chemokine Responses in the Vagina and Serves as a Potent Th1-Tilting Adjuvant for Recombinant gD2 Protein Vaccination against Genital Herpes , 2006, Journal of Virology.

[36]  M. Lederman,et al.  Microbicides and other topical strategies to prevent vaginal transmission of HIV , 2006, Nature Reviews Immunology.

[37]  C. Ripamonti,et al.  Induction of human immunodeficiency virus neutralizing antibodies using fusion complexes. , 2006, Microbes and infection.

[38]  F. Chiodi,et al.  Loss of IL-7Rα is associated with CD4 T-cell depletion, high interleukin-7 levels and CD28 down-regulation in HIV infected patients , 2005, AIDS.

[39]  A. Iwasaki,et al.  Peyer's patch dendritic cells as regulators of mucosal adaptive immunity. , 2005, Cellular and molecular life sciences : CMLS.

[40]  J. Lisziewicz,et al.  DermaVir, a novel HIV immunisation technology. , 2005, Vaccine.

[41]  Praveen Elamanchili,et al.  Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. , 2004, Vaccine.

[42]  R. Effros.  Impact of the Hayflick Limit on T cell responses to infection: lessons from aging and HIV disease , 2004, Mechanisms of Ageing and Development.

[43]  P. Ogra,et al.  Vaccination Strategies for Mucosal Immune Responses , 2001, Clinical Microbiology Reviews.

[44]  E. Vicenzi,et al.  Envelope-Dependent Restriction of Human Immunodeficiency Virus Type 1 Spreading in CD4+ T Lymphocytes: R5 but Not X4 Viruses Replicate in the Absence of T-Cell Receptor Restimulation , 1999, Journal of Virology.

[45]  J. Andersson,et al.  Functional gene transfer of HIV DNA by an HIV receptor-independent mechanism. , 1999, Journal of immunology.

[46]  C. Harley,et al.  Shortened telomeres in the expanded CD28-CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. , 1996, AIDS.

[47]  D. Schmitt,et al.  Epidermal and mucosal dendritic cells and HIV1 infection. , 1994, Pathology, research and practice.

[48]  S. Muyldermans,et al.  Naturally occurring antibodies devoid of light chains , 1993, Nature.

[49]  I. Keet,et al.  Prognostic Value of HIV-1 Syncytium-Inducing Phenotype for Rate of CD4+ Cell Depletion and Progression to AIDS , 1993, Annals of Internal Medicine.

[50]  S. Jeffs,et al.  Repeated vaginal administration of trimeric HIV-1 clade C gp140 induces serum and mucosal antibody responses , 2010, Mucosal Immunology.